Recursion Pharmaceuticals, Inc.
A Salt Lake City company that uses artificial intelligence and automated labs to speed up drug discovery, treating biology like a data problem rather than relying on chance. It was spun out of the University of Utah in 2013 by founders including an MD/PhD student, and its name comes from computer-science "recursion" — the self-improving loop where experimental data trains its AI, which then guides the next experiments. In early tests, its computer-selected drug candidates barely overlapped with ones picked by humans, turning up promising hits that people had missed.
Bought 100.0K
Granted 9.2K
Granted 2.78M · Sold 5.26M
Granted 2.55M · Bought 4.47M
Granted 171.8K · Sold 1.58M
Granted 199.8K · Sold 64.0K
Granted 2.50M · Sold 212.9K
Granted 1.75M · Sold 728.1K
Granted 889.8K · Sold 42.8K
Granted 526.3K
Granted 285.6K · Sold 52.0K
Granted 517.3K · Sold 135.0K
Granted 186.0K · Sold 20.1K
Granted 246.5K
Granted 215.5K
Granted 162.2K
Granted 530.6K · Sold 400.1K
Granted 136.0K
Granted 136.0K · Sold 8.3K
Granted 121.5K
Granted 61.7K · Sold 117.0K
Granted 60.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lux Co-Invest Opportunities, L.P. +3 co-filers10% owner · 4 transactions | — | 34.49Mas of Apr 2021 | — | 100.0K | — |
| Bogue ZacharyDirector, 10% owner · 18 transactions | — | 13.63Mas of Jul 2023 | 9.2K | — | — |
| Ocko Matthew +6 co-filers10% owner · 9 transactions | — | 13.62Mas of Apr 2021 | — | — | — |
| Hebert Peter +5 co-filersFormer 10% Owner · 1 transaction | — | 13.02Mas of Dec 2021 | — | — | — |
| Gibson ChristopherDirector · 531 transactions | — | 12.52M | 2.78M | — | 5.26M |
| Mamoura Diversified Global Holding PJSC +1 co-filer10% owner · 33 transactions | — | 7.06Mas of Mar 2023 | 2.55M | 4.47M | — |
| Borgeson BlakeDirector · 89 transactions | — | 6.26M | 171.8K | — | 1.58M |
| Li Dean YDirector · 44 transactions | — | 3.45M | 199.8K | — | 64.0K |
| Khan NajatCEO and President, Director · 17 transactions | — | 2.18M | 2.50M | — | 212.9K |
| Secora MichaelChief Financial Officer · 96 transactions | — | 1.49Mas of Nov 2024 | 1.75M | — | 728.1K |
| Taylor Ben RChief Financial Officer · 27 transactions | — | 1.10M | 889.8K | — | 42.8K |
| Hallett DavidChief Scientific Officer · 5 transactions | — | 1.07M | 526.3K | — | — |
| Marriott TinaPresident and COO · 26 transactions | — | 506.9Kas of Nov 2024 | 285.6K | — | 52.0K |
| Larson Tina MarriottPresident and COO · 58 transactions | — | 414.5Kas of Jan 2024 | 517.3K | — | 135.0K |
| Dar ZavainDirector · 21 transactions | — | 235.7K | 186.0K | — | 20.1K |
| Mauro David JChief Medical Officer · 7 transactions | — | 225.4Kas of Nov 2024 | 246.5K | — | — |
| Michor FranziskaDirector · 6 transactions | — | 215.5K | 215.5K | — | — |
| Hershberg RobertDirector · 11 transactions | — | 162.2K | 162.2K | — | — |
| Virani ShafiqueChief Business Officer · 60 transactions | — | 136.7Kas of Jan 2024 | 530.6K | — | 400.1K |
| Sun Elaine DDirector · 3 transactions | — | 136.0K | 136.0K | — | — |
| Bumpus NamandjeDirector · 5 transactions | — | 127.6K | 136.0K | — | 8.3K |
| Doyle RamonaChief Medical Officer · 8 transactions | — | 121.1Kas of May 2022 | 121.5K | — | — |
| Burrell Terry-AnnDirector · 22 transactions | — | 71.3Kas of Jul 2024 | 61.7K | — | 117.0K |
| Chavez R. MartinDirector · 17 transactions | — | 60.1Kas of Apr 2024 | 60.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -4.05M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.